| GPER1在EGFR突变的肺腺癌中的表达 |
| |
| 引用本文： | 王建,李振华,汪颖,刘畅,李定彪. GPER1在EGFR突变的肺腺癌中的表达[J]. 中国肿瘤临床, 2021, 48(8): 395-399. DOI: 10.3969/j.issn.1000-8179.2021.08.497 |
| |
| 作者姓名： | 王建 李振华 汪颖 刘畅 李定彪 |
| |
| 作者单位： | 昆明医科大学附属延安医院胸外科（昆明市650051） |
| |
| 基金项目： | 云南省科技计划项目2018FA044 |
| |
| 摘 要： | 目的 探讨肺腺癌中表皮生长因子受体（epidermal growth factor receptor，EGFR）与G蛋白偶联雌激素受体1（G-protein cou? pled estrogen receptor 1，GPER1）/GPR30之间的关系。 方法 采用免疫组织化学方法检测83例术后肺腺癌组织样本中GPER1的表达，同时收集患者的临床病理资料，采用二代基因测序方法检测相应组织中EGFR基因突变状态，并分析GPER1与EGFR之间的相关性，Western blot检测EGFR野生型肺腺癌细胞A549，EGFR突变型肺腺癌细胞PC-9以及使用吉非替尼处理的PC-9细胞的GPER1表达水平。 结果 GPER1的阳性表达与患者性别、年龄、肿瘤大小、吸烟、分化程度无显著性差异（均P > 0.05）；EGFR突变与肿瘤TNM分期无显著性差异（P=0.542）；GPER1阳性表达与EGFR突变呈正相关（P=0.003）；GPER1在Ⅲ、Ⅳ期肺腺癌中较Ⅰ、Ⅱ期高表达（P=0.008）；在PC-9细胞中使用吉非替尼抑制EGFR活性引起GPER1表达下调。 结论 GPER1在EGFR基因突变型的肺腺癌中的表达高于EGFR野生型肺腺癌，GPER1的表达可能受EGFR活性调控。
|
| 关 键 词： | 腺癌 G蛋白偶联雌激素受体1 表皮生长因子受体 突变 |
| 收稿时间： | 2020-11-16 |
Expression of GPER1 in lung adenocarcinoma with EGFR mutation |
| |
| Affiliation: | Department of Thoracic Surgery, Yan' an Affiliated Hospital of Kunming Medical University, Kunming 650051, China |
| |
| Abstract: | Objective To investigate the relationship between mutated epidermal growth factor receptor (EGFR) and the expression of G-protein coupled estrogen receptor 1 (GPER1)/GPR30 in lung adenocarcinoma. Methods The expression of GPER1 in 83 cases of lung adenocarcinoma after surgery was examined using immunohistochemistry and EGFR gene mutation status in the corresponding tis-sues were detected using second-generation gene sequencing. At the same time, clinical pathological data of the patients were collect-ed and the correlation between GPER1 and EGFR was analyzed. In addition, the expression level of GPER1 in lung adenocarcinoma A549 cells with EGFR wild type, PC-9 cells with EGFR mutation, and PC-9 cells treated with gefitinib were examined by Western blot. Results The positive expression of GPER1 was not correlated with gender, age, tumor size, smoking, and degree of differentiation (P > 0.05) and EGFR mutations were not correlated with tumor TNM staging (P=0.542). Positive GPER1 expression was positively correlated with EGFR mutations (P=0.003) and GPER1 expression was higher in stage Ⅲ and Ⅳ lung adenocarcinoma than in stage Ⅰ and Ⅱ (P= 0.008). In addition, the expression of GPER1 decreased when EGFR signaling pathway was inhibited by gefitinib in PC-9 cells. Conclusions The expression of GPER1 in EGFR- mutated lung adenocarcinoma is higher than that of EGFR wild type lung adenocarcinoma, which suggested that GPER1 expression is regulated by the EGFR signaling pathway. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
